Pulse Biosciences - PLSE Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PLSE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLSE, but not buy additional shares or sell existing shares.
View PLSE analyst ratings or view top-rated stocks.

3 brokers have issued 1-year target prices for Pulse Biosciences' shares. Their PLSE share price forecasts range from $8.50 to $13.00. On average, they anticipate the company's share price to reach $11.17 in the next twelve months. This suggests a possible upside of 597.9% from the stock's current price.
View analysts price targets for PLSE or view top-rated stocks among Wall Street analysts.

Pulse Biosciences' stock was trading at $14.81 at the start of the year. Since then, PLSE stock has decreased by 89.2% and is now trading at $1.60.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our PLSE earnings forecast.

Pulse Biosciences, Inc. (NASDAQ:PLSE) issued its quarterly earnings data on Wednesday, August, 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.07. Pulse Biosciences had a negative net margin of 2,866.34% and a negative trailing twelve-month return on equity of 186.19%. During the same quarter last year, the business posted ($0.57) earnings per share.

2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX).

(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company acted as the underwriters for the IPO.

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Pulse Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Westside Investment Management Inc. (0.60%), Millennium Management LLC (0.40%), Northern Trust Corp (0.24%), Griffin Asset Management Inc. (0.23%), Occudo Quantitative Strategies LP (0.20%) and State Street Corp (0.17%).
View institutional ownership trends.

Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PLSE stock can currently be purchased for approximately $1.60.

Pulse Biosciences (NASDAQ:PLSE) has a market capitalization of $59.40 million and generates $1.42 million in revenue each year. The company earns $-63,660,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis.

The company employs 142 workers across the globe.

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The official website for the company is www.pulsebiosciences.com. The company can be reached via phone at (510) 906-4600 or via email at ir@pulsebiosciences.com.